Follow The Filings

IMMX Immix Biopharma

Immix Biopharma earnings company data as of 4:00 PM ET 10/23

Limited consensus data for this ticker (thin coverage or data-plan limits). Dates may be company-announced rather than sell-side consensus. Calendar and recent prints remain the primary lens when available.

Scheduled

1 period, newest first, nothing reported yet. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 6 Nov EPS — — —
Rev — — —

Insider trades

Open-market buys and sales by IMMX's executives, directors and 10% owners in the last 12 months, from their Form 4s

All IMMX insider trades
  • $10K bought by 2 insiders
  • None no sales outside a trading plan
  • None no planned (10b5-1) sales
  1. Ilya M Rachman CEO
    Buy
    $4,976 746 shares at $6.67 +0.1% to stake
    Traded Dec 10, 2025 Filed Dec 10, 2025
    ↗
  2. Gabriel S Morris CFO
    Buy
    $5,067 770 shares at $6.58 +0.3% to stake
    Traded Dec 10, 2025 Filed Dec 10, 2025
    ↗

Also filed in the last 12 months, not counted as buying or selling: 7 stock grants and 1 option exercise.

SEC filings

Recent issuer filings from EDGAR, 25 shown.

Filed Form Detail Links
8-K 8.01,9.01 Filing Doc
424B5 Filing Doc
8-K 7.01,8.01,9.01 Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G/A — Filing Doc
10-Q Filing Doc
8-K 8.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 5.07 Filing Doc
8-K 7.01,8.01,9.01 Filing Doc
424B5 Filing Doc
8-K 8.01,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
10-Q Filing Doc
SCHEDULE 13G/A — Filing Doc
DEF 14A Filing Doc
DEFA14A Filing Doc
8-K 7.01,8.01,9.01 Filing Doc
10-K/A Filing Doc
10-K Filing Doc
424B5 Filing Doc
8-K 1.01,9.01 Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G — Filing Doc

Source: SEC EDGAR submissions, updated 6 days ago. All on EDGAR

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.